|
| Press Releases |
|
 |
|
| Monday, March 13, 2017 |
|
|
雅各臣公布收购康宁行70%权益 |
| 从事非专利药及品牌药品研发、生产、市场推广及销售的领先企业－雅各臣科研制药有限公司（「雅各臣」或「集团」；股份代号：2633）今天公布收购康宁行集团（包括「康宁行有限公司」及其香港附属公司）的70%权益，总代价为56,000,000港元。 more info >> |
|
|
雅各臣公布收購康寧行70%權益 |
從事非專利藥及品牌藥品研發、生產、市場推廣及銷售的領先企業－雅各臣科研製藥有限公司（「雅各臣」或「集團」；股份代號：2633）今天公佈收購康寧行集團（包括「康寧行有限公司」及其香港附屬公司）的70%權益，總代價為56,000,000港元。完成收購後，康寧行集團將成為雅各臣間接非全資附屬公司。
more info >> |
|
|
Jacobson Pharma Announces Acquisition of 70% Interest in Hong Ning Hong |
| Jacobson Pharma Corporation Limited ("Jacobson Pharma" or the "Group"; Stock Code: 2633), a leading company engaged in the research, development, production more info >> |
|
| Wednesday, January 18, 2017 |
|
|
雅各臣收购「十灵丹」、「十灵油」及「伤风克」建立具扩展性平台 |
从事非专利药及品牌药品研发、生产、市场推广及销售的领先企业－雅各臣科研制药有限公司（「雅各臣」或「集团」；股份代号：2633）今天公布收购一系列家喻户晓的药品品牌，包括「十灵丹」、「十灵油」及「伤风克」。
more info >> |
|
|
雅各臣收購「十靈丹」、「十靈油」及「傷風克」建立具擴展性平台 |
從事非專利藥及品牌藥品研發、生產、市場推廣及銷售的領先企業－雅各臣科研製藥有限公司（「雅各臣」或「集團」；股份代號：2633）今天公佈收購一系列家喻戶曉的藥品品牌，包括「十靈丹」、「十靈油」及「傷風克」。
more info >> |
|
|
Jacobson Pharma to Acquire Saplingtan, Shiling Oil & Col-gan Tablet; Creating an Expandable Proprietary Medicine Platform |
Jacobson Pharma Corporation Limited ("Jacobson Pharma" or the "Group"; Stock Code: 2633), a leading company engaged in the research, development, production, marketing and sale of generic drugs and proprietary medicines, today announced its acquisition of a family of popular household brands, namely, Saplingtan, Shiling Oil and Col-gan Tablet.
more info >> |
|
| Tuesday, December 13, 2016 |
|
|
雅各臣公布完成收购「何济公」之100%权益 |
| 从事非专利药及品牌药品研发、生产、市场推广及销售的领先企业—雅各臣科研制药有限公司（「雅各臣」或「集团」；股份代号：2633）今天宣布完成收购目标集团（由「嘉伦药业有限公司」、「永生药业有限公司」及「香港何济公药厂有限公司」组成），该目标集团拥有传统居家品牌「何济公」之100%权益，总代价为568,000,000港元。 more info >> |
|
|
雅各臣公佈完成收購「何濟公」之100%權益 |
| 從事非專利藥及品牌藥品研發、生產、市場推廣及銷售的領先企業—雅各臣科研製藥有限公司（「雅各臣」或「集團」；股份代號：2633）今天宣佈完成收購目標集團（由「嘉倫藥業有限公司」、「永生藥業有限公司」及「香港何濟公藥廠有限公司」組成），該目標集團擁有傳統居家品牌「何濟公」之100%權益，總代價為568,000,000港元。 more info >> |
|
|
Jacobson Pharma Announces Acquisition of 100% Interest in Ho Chai Kung Brand |
| Jacobson Pharma Corporation Limited ("Jacobson Pharma" or the "Group"; Stock Code: 2633), a leading company engaged in the research, development, production, marketing and sale of generic drugs and proprietary Chinese medicines, today announces the acquisition of 100% interest in a Target Group (comprising "Karen Pharmaceutical Company Limited" more info >> |
|
| Wednesday, November 23, 2016 |
|
|
雅各臣公布二零一六年中期业绩 |
从事非专利药及中成药研发、生产、市场推广及销售的领先企业，以及香港最大的非专利药公司─雅各臣科研制药有限公司（「雅各臣」或「公司」；股份代号：2633 ）今天公布公司及附属公司（统称「集团」）截至二零一六年九月三十日止六个月（「报告期」）的未经审核中期业绩。
more info >> |
|
|
|
|
|
|
|
|
|
| Latest Press Releases |
|
Your Go-To Travel Checklist for Smarter, Reward-Focused Travel Planning
May 18, 2026 11:12 HKT/SGT
|
|
|
JCB and Wonder Advance Cashless Taxi Payments in Hong Kong
May 18, 2026 10:00 JST
|
|
|
「星樞計劃」正式發布 鈞達股份多家下屬公司成為上海太空算力產業生態夥伴發起及首批單位
May 17, 2026 12:51 HKT/SGT
|
|
|
Shoucheng Holdings' First-Quarter Report Shows 18% Core Profit Growth and Sustained High Shareholder Returns
May 16, 2026 08:49 HKT/SGT
|
|
|
首程控股一季報核心利潤增長18% 高股東回報持續兌現
May 16, 2026 08:49 HKT/SGT
|
|
|
Tabor Redefines Anti-Drone Testing with Software-Defined SDR Platform
May 16, 2026 07:00 HKT/SGT
|
|
|
NEC completes construction of approximately 2,250 km EMCS submarine cable linking Pacific island nations
May 15, 2026 17:36 JST
|
|
|
Fujitsu and Science Tokyo launch joint research hub for quantum hardware advancement and talent development
May 15, 2026 17:12 JST
|
|
|
Fujitsu and IBM Japan formalize collaboration in healthcare sector
May 15, 2026 16:42 JST
|
|
|
三菱重工機械システム、関越自動車道での交通混雑緩和キャンペーンに協力
May 15, 2026 15:30: JST
|
|
|
富士通と東京科学大学、量子ハードウェア技術の進展と人材育成に向けた共同研究を開始
May 15, 2026 15:30: JST
|
|
|
Toyota Launches All-New Land Cruiser "FJ" Series in Japan
May 15, 2026 15:24 JST
|
|
|
Mitsubishi Motors Signs Memorandum of Understanding with FPT Japan Holdings to Study Collaboration in Software and Digital Domain
May 15, 2026 15:10 JST
|
|
|
NEC Launches Orbital Transfer Vehicle Development Project Aiming for Asia's First Vehicle Deployment through JAXA's Space Strategy Fund Program
May 15, 2026 14:55 JST
|
|
|
Substantial Shareholder Wei Fu Increases Shareholding in Everest Medicines Again, Marking His Second Share Purchase in 2026 and Demonstrating Long-term Confidence
May 15, 2026 13:00 HKT/SGT
|
|
|
|
|
More News >> |
|
|
|
|
|
